ApoB and Lp(a) in Women: The Lipid Truth After 45

Her LDL was 118 at her annual physical, her physician called it well-controlled, and nobody ordered anything else. Her ApoB was 112. Her Lp(a) was 87 mg/dL. She had preeclampsia documented in her OB records that never made it into her primary care chart. She was 47, and the standard cardiovascular risk calculator called her low risk. By an accurate assessment of her lipid biology and pregnancy history, she was not.

The Mechanism

The standard lipid panel measures four numbers: total cholesterol, LDL, HDL, and triglycerides. Of these, LDL gets the most clinical attention. But LDL measures the mass of cholesterol packed inside particles, not the number of particles circulating in blood. That distinction becomes consequential at midlife in women, and here is why.

Every atherogenic lipoprotein particle, whether LDL, VLDL, or IDL, carries exactly one molecule of apolipoprotein B on its surface. ApoB is a structural protein: one particle, one ApoB. Measuring ApoB therefore gives a direct count of the atherogenic particles in circulation. LDL does not. Consider two women, both with LDL of 118 mg/dL. Woman A has 80 large, buoyant LDL particles, each carrying a generous cholesterol load. Woman B has 120 small, dense LDL particles, each carrying less cholesterol per particle but totaling the same cholesterol mass. Their LDL readings are identical. Woman B’s ApoB is 50 percent higher. These two women do not have the same cardiovascular risk profile.

Small dense LDL is the more dangerous phenotype. It penetrates the arterial wall more readily than large buoyant LDL, it oxidizes more easily once inside the wall, and it is cleared from circulation more slowly because it binds less efficiently to LDL receptors. Its accumulation in the arterial intima is a direct driver of atherosclerotic plaque formation and progression.

The perimenopausal transition accelerates the development of this phenotype through two converging pathways. First, estrogen upregulates LDL receptors in the liver. As estrogen declines during perimenopause, LDL receptor expression falls, hepatic clearance of LDL slows, and circulating LDL rises. The SWAN (Study of Women’s Health Across the Nation) cohort documented a mean LDL increase of approximately 10 to 15 mg/dL across the menopausal transition. This is not a dietary artifact and not a rounding error. It reflects the loss of estrogen’s lipid-protective mechanism.

Second, the perimenopausal metabolic shift drives increasing insulin resistance and visceral fat accumulation, which together raise hepatic VLDL production. Elevated VLDL triggers cholesterol ester transfer protein (CETP) activity, which exchanges triglycerides for cholesterol between VLDL and LDL particles. The result is a remodeling of LDL: larger particles shed cholesterol content and become the small, dense, more atherogenic variety. A woman whose LDL rises from 105 to 122 at menopause may have seen her ApoB rise from 80 to 110, a proportionally far larger increase in atherogenic particle burden than the LDL numbers suggest. The lipid panel shows a modest LDL rise. The ApoB reveals a substantially worsened atherogenic profile.

Lipoprotein(a), written Lp(a) and pronounced “L-P-little-a,” adds a separate and additive layer of risk. Lp(a) is a variant of LDL in which an additional protein, apolipoprotein(a), is covalently bonded to the ApoB on the LDL particle. Apolipoprotein(a) is structurally similar to plasminogen, the protein that dissolves blood clots. Because of this structural mimicry, Lp(a) competitively inhibits fibrinolysis: it occupies plasminogen-binding sites on fibrin and on endothelial cells, impairing the body’s ability to dissolve clots. A particle that simultaneously deposits cholesterol in arterial walls and impairs clot clearance is acting through two independent atherogenic mechanisms.

Lp(a) also carries oxidized phospholipids that promote endothelial inflammation and calcification. The association between elevated Lp(a) and calcific aortic stenosis is one of the stronger lipid-disease relationships in cardiology.

Critically, Lp(a) concentration is almost entirely determined by genetics. Diet does not lower it. Exercise does not lower it. Statins do not lower it in any clinically meaningful way. A woman’s Lp(a) level at 47 is approximately what it was at 25 and what it will be at 65. One measurement is sufficient for lifetime risk stratification.

What the Evidence Shows

The evidence establishing ApoB as a superior predictor of cardiovascular events compared to LDL is not new and not from small studies. The INTERHEART study, published in The Lancet in 2004 by Yusuf and colleagues, enrolled more than 27,000 participants across 52 countries and found that the ApoB-to-ApoA1 ratio was a stronger predictor of myocardial infarction than LDL or total cholesterol in every geographic region and ethnic group studied. The AMORIS study, published in The Lancet in 2001 by Walldius and colleagues, followed more than 175,000 Swedish adults and found that ApoB predicted cardiovascular mortality more strongly than LDL in both men and women. A 2021 Mendelian randomization analysis in the European Heart Journal by Ference and colleagues demonstrated that ApoB-lowering, independent of the specific intervention used to achieve it, predicted cardiovascular benefit, supporting ApoB rather than LDL as the causal lipid variable.

For Lp(a) specifically, the Copenhagen City Heart Study and Copenhagen General Population Study, analyzed by Falk, Nordestgaard, and colleagues and published in the Journal of the American College of Cardiology in 2016, followed more than 100,000 individuals and found that Lp(a) above 50 mg/dL was associated with a 1.5 to 3 fold increase in cardiovascular risk independent of LDL, ApoB, and traditional risk factors. The risk increase was log-linear: higher Lp(a) conferred continuously higher risk. Nordestgaard and colleagues also established in a 2010 European Heart Journal paper that Lp(a) above 50 mg/dL affects approximately 20 percent of the general population, making it one of the most prevalent single-gene cardiovascular risk factors in existence.

The racial disparity in Lp(a) levels is documented and clinically underappreciated. Data from the Dallas Heart Study, published by Gidding and colleagues, and from multiple population cohorts consistently show that mean Lp(a) levels in Black Americans are approximately 2 to 3 times higher than in White or Asian Americans. This is a genetic population difference. It is not explained by diet, income, access, or lifestyle variables. A Black woman with LDL of 115 who has never had Lp(a) measured may carry Lp(a) of 90 mg/dL, a combination that places her at substantially higher cardiovascular risk than her standard lipid panel would indicate. The 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease identifies Lp(a) as a risk-enhancing factor that should prompt consideration of statin therapy when the decision is otherwise uncertain. For Black women, measurement is not optional if cardiovascular risk assessment is to be accurate.

On current treatment options: PCSK9 inhibitors (evolocumab and alirocumab) lower Lp(a) by approximately 20 to 25 percent, a partial reduction that is a secondary effect of their primary LDL-lowering mechanism. Niacin was once used for Lp(a) reduction but is no longer recommended following the HPS2-THRIVE trial, published in the New England Journal of Medicine in 2014, which showed no cardiovascular outcome benefit from niacin added to statin therapy despite favorable lipid changes. Two RNA-targeted therapies are currently in Phase 3 trials: pelacarsen (a small interfering RNA that reduces hepatic apolipoprotein(a) production) and olpasiran (a GalNAc-conjugated siRNA). Both have demonstrated Lp(a) reductions of 70 to 90 percent in Phase 2 data. FDA review is anticipated within the next two to three years.

ApoB Targets and Residual Risk: What the Threshold Numbers Are Based On

Understanding what drives the ApoB threshold numbers used in clinical guidelines requires looking at both the mechanistic evidence base and the trial data that translated it into treatment targets. The 2021 European Society of Cardiology lipid guidelines define ApoB thresholds as follows: below 65 mg/dL for very high cardiovascular risk (established atherosclerotic disease or diabetes with organ damage), below 80 mg/dL for high risk (significantly elevated single risk factors, or 10-year cardiovascular risk between 10 and 20%), and below 100 mg/dL for moderate risk (10-year risk below 10%). These are not arbitrary numbers. They derive from a combination of randomized trial outcome data and Mendelian randomization studies establishing what ApoB levels at lifetime exposure correspond to low cardiovascular event rates.

The Cholesterol Treatment Trialists’ Collaboration, reporting a meta-analysis in The Lancet in 2010 covering 170,000 participants across 26 statin trials, established the linear relationship between LDL reduction and cardiovascular event reduction: each 1 mmol/L reduction in LDL-C was associated with a 22% relative risk reduction in major vascular events. When this relationship is recast in terms of atherogenic particle reduction rather than cholesterol mass, the data argue that what matters most is how many atherogenic particles remain in circulation after treatment, which is what ApoB measures directly.

The residual risk problem becomes clinically visible in a JUPITER trial sub-analysis published by Boekholdt and colleagues in the European Heart Journal in 2012. Among participants who achieved LDL below 70 mg/dL on rosuvastatin — a level many clinicians would consider well-controlled — those with ApoB above 80 mg/dL had significantly higher rates of major cardiovascular events than those with ApoB below 80 mg/dL. Their LDL was at target. Their particle burden was not. This is the precise clinical scenario that perimenopausal women with discordance are at risk for: an LDL reading that falls within the treated range while the ApoB remains elevated because small, dense, cholesterol-depleted particles are not being counted by the cholesterol mass measurement.

The implication is that reaching an LDL target without measuring ApoB creates a monitoring gap that is clinically meaningful in the population where discordance is most likely. In a postmenopausal woman on statin therapy, both measurements belong in the annual follow-up.

What to Do This Week

1. Request ApoB added to your next lipid panel. Ask your physician or order through a direct-to-consumer lab (LabCorp Patient Direct, Quest Direct, Function Health, Boston Heart Diagnostics). ApoB is generally insurance-covered when ordered alongside a standard lipid panel. You do not need to fast specifically for ApoB, though fasting is standard for a complete lipid panel. If your ApoB comes back above 90 mg/dL, ask your physician to discuss what target is appropriate given your full risk profile. ApoB below 90 mg/dL is the threshold for average cardiovascular risk; below 70 mg/dL for elevated risk; below 60 mg/dL for very high risk.

2. Request Lp(a) measured once. Fasting is not required. Ask for results reported in both mg/dL and nmol/L, as laboratories use different assays and conversion between units is not linear. Above 50 mg/dL (above 100 nmol/L) is the threshold for elevated risk in most published guidelines. If you are a Black woman and have never had Lp(a) measured, treat this as an urgent gap in your cardiovascular risk assessment, not an optional add-on.

3. Bring your obstetric history into your cardiovascular record. If you had preeclampsia, gestational hypertension, gestational diabetes, preterm birth, or a small-for-gestational-age infant, these conditions are independent cardiovascular risk factors that belong in your primary care and cardiology charts. They are routinely siloed in OB records and never incorporated into longitudinal risk assessment. Write them down, bring documentation to your next appointment, and ask that they be entered into your problem list.

4. If you are in perimenopause, request a lipid panel that includes ApoB now. The perimenopausal window is the period of most rapid lipid change. A baseline ApoB obtained at the beginning of the transition allows your physician to track the trajectory of atherogenic particle burden rather than learning about it after the fact. If your LDL has risen since age 40, do not accept the explanation that this is dietary without ApoB data to characterize whether the particle phenotype has shifted.

5. If your ApoB is above 70 mg/dL and your Lp(a) is above 50 mg/dL, ask your physician directly: “Given both of these values together, what is my revised cardiovascular risk and what is the treatment threshold we are using?” That specific question, with both numbers in hand, moves the conversation from reassurance to evidence-based risk calculation. If your physician is unfamiliar with ApoB targets or Lp(a) risk modification, ask for a cardiology referral or a preventive cardiologist specifically.

The woman in the opening of this article did not have a communication failure. She had a measurement failure: the numbers that were ordered did not capture the biology that was present. The fix is not more careful interpretation of the standard lipid panel. It is ordering the tests that measure what actually matters. ApoB and Lp(a) are available, covered, and interpretable now. They belong in the standard cardiovascular risk evaluation for every woman at and after 45, and for Black women, they belong there without exception.

Related reading:

• The Five Numbers That Define Your Cardiac Baseline
• The Women’s Cardiac Screening Lab Panel
• 59% of Black Women Have Cardiovascular Disease